Resource Logo
NLM AIDSLINE

New drug pricing consensus letter, sign-ons requested.




 

AIDS Treat News. 1998 Sep 4;(302):4. Unique Identifier : AIDSLINE

Treatment activists are circulating a letter opposing drug-pricing strategies for abacavir (Ziagen) and efavirenz (Sustiva). The groups are concerned that these drugs will be priced significantly higher than other nucleoside analogs and non-nucleoside reverse transcriptase inhibitors. The statement notes that higher survival rates should insure drug manufacturers of a steady supply of patients, allowing them to lower prices and still make a profit. Both drugs are appropriate for treatment-naive and treatment-experienced patients, making the potential market for them large. The letter is sponsored by the Fair Price Working Group, which includes members from Project Inform, ACT UP/New York, the San Francisco AIDS Foundation, GMHC Treatment Issues, Foundation for AIDS and Immune Research, and AIDS Treatment News. Contact information is included.

NEWSLETTER ARTICLE Anti-HIV Agents/*ECONOMICS/THERAPEUTIC USE Dideoxynucleosides/*ECONOMICS/*THERAPEUTIC USE *Economics, Pharmaceutical HIV Infections/*DRUG THERAPY/ECONOMICS Human Oxazines/*ECONOMICS/THERAPEUTIC USE Reverse Transcriptase Inhibitors/*ECONOMICS/THERAPEUTIC USE United States



 




Information in this article was accurate in July 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.